X4 Pharmaceuticals (XFOR) Stifel 2026 Healthcare Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Stifel 2026 Healthcare Conference 2026 summary
12 Nov, 2026Operational reset and 4WARD trial
Refinancing and new management followed in July and August last year; costs and headcount were reduced, and the team refocused on the pivotal 4WARD trial.
Planned enrollment was reduced from 176 to 126, retaining 89% power for the infection endpoint and 93% for ANC; blinded baseline characteristics supported the change.
Parexel partnership improved trial operations; recent months brought the strongest screening-to-randomization dynamics to date.
Enrollment is targeted to close by year-end 2026, with topline phase III chronic neutropenia data expected in Q1 2028.
Trial assumptions include ~1/3 lower infection rate and at least 1/3 of patients achieving an ANC increase of 500 cells/µL on at least 3 occasions over 12 months.
Clinical evidence and safety
Blinded baseline profile: median age 36; 68% had at least 3 infections, versus 2 required for enrollment; ~37% were receiving G-CSF.
Small phase II dataset showed mavorixafor could normalize ANC in patients with low counts and allow G-CSF dose reduction in patients with higher ANC; ~70% overall reduced G-CSF, with some stopping it.
A blinded independent committee, including hematology and infectious disease specialists, adjudicates infections; minor mouth ulcers do not qualify, and blinded events were tracking as expected.
No new safety signals had emerged with longer exposure; reported GI toxicity can be treated symptomatically and appears to resolve after a couple of weeks.
Market opportunity and commercial outlook
Expected label base case: symptomatic chronic neutropenia, with claims related to reducing infections and their severity or duration; a broader symptomatic label could expand the opportunity from 15,000 to 30,000 patients.
Market research indicated 95,000 patients with primary chronic neutropenia, 30,000 symptomatic patients, and 15,000 with at least 2 infections; claims, physician surveys, patient input, and advisory boards informed estimates.
In 2025, 6,300 patients were hospitalized with the condition, with a median stay of 4 days; severely neutropenic patients, including those with ANC below 1,000, were highlighted as an initial treatment focus.
A personal pricing estimate was $250,000-$350,000 per year, versus $585,000 per year for WHIM, which was viewed as unsustainable for the larger market.
Latest events from X4 Pharmaceuticals
- 4WARD enrollment is targeted for year-end 2026; top-line results are expected in Q1 2028.XFOR
3rd Annual Guggenheim Healthcare Innovation Conference - Higher product sales and 4WARD progress accompany debt refinancing and runway into Q1 2029.XFOR
Q3 2026 - Mavorixafor’s PCN opportunity pairs a ~15,000-patient base with Q1 2028 readouts.XFOR
Investor Day 2026 - 4WARD topline data are expected in H1 2028, backed by Phase 2 evidence of ANC gains and reduced G-CSF use.XFOR
Corporate presentation - Phase III enrollment nears completion, with launch targeted for late 2028 or early 2029.XFOR
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue was $8.8M, net loss improved, and cash runway extends into 2029.XFOR
Q2 2026 - XOLREMDI launch gains traction as Phase 3 CN trial advances and global expansion plans progress.XFOR
Stifel 2024 Healthcare Conference - Q2 net income hit $90.8M on $105M PRV sale and XOLREMDI U.S. launch.XFOR
Q2 2024 - Mavorixafor durably increased ANC and showed good tolerability in chronic neutropenia Phase 2.XFOR
Study Update